


Stopping NUCs how to move forward? (with incomplete knowledge...)






Dr Kosh Agarwal
Institute of Liver Studies
King's College Hospital
London

HBV Forum 2021

Stopping NA therapy before HBsAg loss in HBeAg-negative patients



Viral and immune factors associated with successful withdrawal in HBeAg –ve HBV



Se	Sp	PPV	NPV	LR ⁺	LR ⁻
88%	79%	64%	94%	4.16	0.16

Low SAg
Decreased cccDNA
Transcription
Functional HBV specific
T cells at baseline

N=27 – 30% lost SAg/ 82% not retreated

‘When all think alike, no one thinks very much...’

W Lippman

No clinical consensus

Not a big uptake in clinical practice – pts!

What endpoint? – surely SAg loss

Low SAg <100 – lower the better

Conflicting evidence re newer viral biomarkers


Viral/ host heterogeneity confusing

Transcriptional activity vs invigorated T cell response*

Pragmatic criteria (HBV EAg loss, HBSAg<100, composite)

Standardise – ie everyone and then watch...

or consider MOA driven rules



*'Dylan' refined proposal Berg T, Lampertico P J Hep *in press*